AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7847516 — intervention group
Group type: COMPARATOR
Intervention: Oral estrogen (2 mg of estradiol valerate and 1 mg of norethisterone acetate daily)
Number of subjects: 40
Study 1752280 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐VAC (modified methotrexate, vinblastine, adriamycin and cisplatin)
Number of subjects: 28
Study 1752280 — intervention group
Group type: COMPARATOR
Intervention: MP (methotrexate followed by folinic acid rescue and cisplatin)
Number of subjects: 28
Study 1752280 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐VAC
Number of subjects: 28
Study 1752280 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 28
Study 7074558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA)
Number of subjects: 12
Study 7074558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of megestrol, cyclophosphamide, doxorubicin, and 5-fluorouracil (MCAF)
Number of subjects: 12
Study 7074558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of megestrol, 1-phenylalanine mustard, and 5-fluorouracil (MLF)
Number of subjects: 12
Study 7074558 — intervention group
Group type: EXPERIMENTAL
Intervention: MCA
Number of subjects: 12
Study 7074558 — intervention group
Group type: COMPARATOR
Intervention: MCAF
Number of subjects: 12
Study 31994751 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) knee implant
Number of subjects: 74
Study 31994751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) knee implant
Number of subjects: 74
Study 31994751 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-stabilized (MS) knee implant
Number of subjects: 74
Study 31994751 — intervention group
Group type: COMPARATOR
Intervention: Healthy knee
Number of subjects: 74
Study 31498414 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually customized IOL (HumanOptics AG, Erlangen, Germany)
Number of subjects: 60
Study 31498414 — intervention group
Group type: COMPARATOR
Intervention: Standard spherical aberration-correcting IOL (Tecnis ZCB00; Johnson & Johnson Vision Surgical, Inc., Santa Ana, CA)
Number of subjects: 60
Study 28236615 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music and exercise training (MT) group
Number of subjects: 74
Study 28236615 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training only (T) group
Number of subjects: 74
Study 28236615 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music only (M) group
Number of subjects: 74
Study 26310261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous elafin 200 mg
Number of subjects: 87
Study 26310261 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 87
Study 24316098 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive double-layered tablet formulation (GSS)
Number of subjects: 9
Study 22724877 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (220 mg capsules, three times daily until end of chemotherapy)
Number of subjects: 50
Study 22724877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three placebo capsules daily)
Number of subjects: 50
Study 22724877 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Number of subjects: 50
Study 19685943 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood induction night
Number of subjects: 28
Study 19685943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood induction night
Number of subjects: 28
Study 17462083 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based multifactorial fall prevention programme
Number of subjects: 513
Study 15175869 — intervention group
Group type: EXPERIMENTAL
Intervention: Preplanning based on pretherapeutic transrectal ultrasound for the first HDR brachytherapy implant.
Number of subjects: 15
Study 15175869 — intervention group
Group type: EXPERIMENTAL
Intervention: Preplanning based on ultrasound from the first HDR brachytherapy implant for the second HDR brachytherapy.
Number of subjects: 15
Study 15175869 — intervention group
Group type: COMPARATOR
Intervention: Postplans compared to preplans for both HDR brachytherapy implants.
Number of subjects: 15
Study 11937460 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 6000
Study 11937460 — intervention group
Group type: COMPARATOR
Intervention: Maximum medical therapy
Number of subjects: 6000
Study 11937460 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transmyocardial laser revascularization (PMR)
Number of subjects: 6000
Study 11475718 — intervention group
Group type: EXPERIMENTAL
Intervention: Weihuigui Decoction (WHGD) 100 ml, three times a day for 2 weeks
Number of subjects: 64
Study 11475718 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 64
Study 10332645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection program including curricular materials, training and support for staff, and parent outreach.
Number of subjects: 4200
Study 10332645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection program
Number of subjects: 4200
Study 2068471 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 300
Study 2068471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 6861846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg p.o.)
Number of subjects: 9
Study 6861846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9
Study 6861846 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg thrice daily)
Number of subjects: 9
Study 30897983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol-containing ointment
Number of subjects: 38
Study 30897983 — intervention group
Group type: COMPARATOR
Intervention: Petroleum jelly
Number of subjects: 38
Study 29275906 — intervention group
Group type: COMPARATOR
Intervention: Stress management training (n=65) including self-awareness, focus, relaxation, positive self-talk, visualization, and team building.
Number of subjects: 137
Study 29275906 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=72) without stress management training.
Number of subjects: 137
Study 26841799 — intervention group
Group type: EXPERIMENTAL
Intervention: COTiD-UK
Number of subjects: 480
Study 26841799 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (VALID programme)
Number of subjects: 480
Study 25223320 — intervention group
Group type: EXPERIMENTAL
Intervention: GtxA-N
Number of subjects: 0
Study 25223320 — intervention group
Group type: EXPERIMENTAL
Intervention: FlfA
Number of subjects: 0
Study 25223320 — intervention group
Group type: EXPERIMENTAL
Intervention: Gab_1309
Number of subjects: 0
Study 22306394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 123
Study 22306394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 123
Study 22306394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Number of subjects: 123
Study 20169359 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (CHO)
Number of subjects: 24
Study 18086763 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate breast cancer education program
Number of subjects: 776
Study 18086763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 776
Study 15763533 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP)
Number of subjects: 124
Study 15763533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradycardia prevention pacing (BPP)
Number of subjects: 124
Study 15763533 — intervention group
Group type: COMPARATOR
Intervention: No pacing (NP)
Number of subjects: 124
Study 12016079 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive positioning of the shoulder in midrange positions
Number of subjects: 6
Study 9257738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily from day -2 to day 2)
Number of subjects: 15
Study 9257738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily from day -2 to day 0)
Number of subjects: 15
Study 9257738 — intervention group
Group type: COMPARATOR
Intervention: Sparfloxacin alone (400 mg single oral dose on day 0)
Number of subjects: 15
Study 8290678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/day)
Number of subjects: 28
Study 8290678 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine (6 mg/day)
Number of subjects: 28
Study 8290678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3579261 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (40 mg/kg per day) for 5 days
Number of subjects: 100
Study 3579261 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 100
Study 29888939 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating training
Number of subjects: 197
Study 29888939 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-to-context binding training
Number of subjects: 197
Study 29888939 — intervention group
Group type: COMPARATOR
Intervention: Active control group practicing visual search tasks
Number of subjects: 197
Study 28033691 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg/day for week 1; 20 mg/day for weeks 2-6) plus olanzapine (15-20 mg/day)
Number of subjects: 0
Study 28033691 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 0
Study 24448288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early (1-wk) switch-on group
Number of subjects: 17
Study 24448288 — intervention group
Group type: COMPARATOR
Intervention: Control group (switch-on after 4 wks)
Number of subjects: 17
Study 22076437 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate doses of lithium
Number of subjects: 283
Study 22076437 — intervention group
Group type: COMPARATOR
Intervention: No lithium (control group)
Number of subjects: 283
Study 20663600 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomies with endodontic treatments
Number of subjects: 10
Study 20663600 — intervention group
Group type: COMPARATOR
Intervention: Coronectomies without endodontic treatment
Number of subjects: 10
Study 17997267 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly vouchers to reinforce abstinence and positive behaviors
Number of subjects: 163
Study 17997267 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vouchers)
Number of subjects: 163
Study 16393332 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic administration of penicillin G and V (Group A)
Number of subjects: 20
Study 16393332 — intervention group
Group type: COMPARATOR
Intervention: No repeated penicillin administration (Group B)
Number of subjects: 20
Study 12847368 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam
Number of subjects: 251
Study 12847368 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone foam
Number of subjects: 251
Study 12847368 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam (subgroup of non-responders to mesalamine)
Number of subjects: 251
Study 12847368 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone foam (subgroup of non-responders to mesalamine)
Number of subjects: 251
Study 10385012 — intervention group
Group type: EXPERIMENTAL
Intervention: BacT/Alert FAN bottle
Number of subjects: 945
Study 10385012 — intervention group
Group type: COMPARATOR
Intervention: BacT/Alert STD bottle
Number of subjects: 945
Study 10385012 — intervention group
Group type: EXPERIMENTAL
Intervention: BacT/Alert system
Number of subjects: 945
Study 10385012 — intervention group
Group type: COMPARATOR
Intervention: ISO tube
Number of subjects: 945
Study 9032580 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosulide (20 mg twice a day)
Number of subjects: 19
Study 9032580 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 19
Study 1442478 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) infusion
Number of subjects: 100
Study 1442478 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 100
Study 4066373 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin instillation therapy
Number of subjects: 95
Study 4066373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mitomycin treatment)
Number of subjects: 95
Study 30607812 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading comprehension intervention
Number of subjects: 280
Study 30607812 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing intervention (teacher-led computer-supported)
Number of subjects: 280
Study 30607812 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group interviews and observations
Number of subjects: 280
Study 30607812 — intervention group
Group type: EXPERIMENTAL
Intervention: Artifact review of school curricula and PD plans
Number of subjects: 280
Study 29589328 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic removal of obstructive IVH using external ventricular drainage
Number of subjects: 500
Study 26970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory approach implementation strategy including working group meetings, supervisor training, and optional coaching.
Number of subjects: 116
Study 26970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Working group meetings and supervisor training.
Number of subjects: 116
Study 26970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching for supervisors (optional).
Number of subjects: 116
Study 26970753 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implementation strategy.
Number of subjects: 116
Study 25269022 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate and naltrexone
Number of subjects: 74
Study 22370004 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a cognitive behaviour therapy (CBT) booklet (BUC)
Number of subjects: 0
Study 22370004 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise therapy (GET)
Number of subjects: 0
Study 22370004 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (COUNS)
Number of subjects: 0
Study 22370004 — intervention group
Group type: COMPARATOR
Intervention: GET
Number of subjects: 0
Study 22370004 — intervention group
Group type: COMPARATOR
Intervention: COUNS
Number of subjects: 0
Study 19888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool form (Bristol Stool Scale)
Number of subjects: 110
Study 19888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Bristol stool form value <3
Number of subjects: 110
Study 19888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool frequency
Number of subjects: 110
Study 17956953 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (individualized dose titration regimen)
Number of subjects: 29
Study 17956953 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (fixed body weight-based dosing regimen)
Number of subjects: 29
Study 17956953 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (both dosing regimens combined)
Number of subjects: 29
Study 16160131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (79.2 Gy)
Number of subjects: 393
Study 16160131 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose radiation therapy (70.2 Gy)
Number of subjects: 393
Study 12100367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneously once daily)
Number of subjects: 212
Study 12100367 — intervention group
Group type: COMPARATOR
Intervention: UFH (5000 IU subcutaneously thrice daily)
Number of subjects: 212
Study 10439108 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 4 cm H2O
Number of subjects: 0
Study 10439108 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 7 cm H2O
Number of subjects: 0
Study 10439108 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 10 cm H2O
Number of subjects: 0
Study 8555803 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and dopa decarboxylase inhibitor (arm 1)
Number of subjects: 520
Study 8555803 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and decarboxylase inhibitor in combination with selegiline (arm 2)
Number of subjects: 520
Study 2355103 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (100 mg bid)
Number of subjects: 34
Study 2355103 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) (25 mg bid)
Number of subjects: 34
Study 2355103 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 34
Study 2355103 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Number of subjects: 34
Study 872445 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term diphenylhydantoin (DPH) treatment
Number of subjects: 0
Study 872445 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of DPH treatment
Number of subjects: 0
Study 30927200 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program for 16 weeks
Number of subjects: 39
Study 30927200 — intervention group
Group type: COMPARATOR
Intervention: No change in regular physical activity (control group)
Number of subjects: 39
Study 30056040 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 752
Study 30056040 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection vs full resection
Number of subjects: 752
Study 28885425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mL 1% lidocaine paracervical nerve block
Number of subjects: 95
Study 28885425 — intervention group
Group type: COMPARATOR
Intervention: Sham block (1 cm depression of the vaginal epithelium at paracervical block sites with a wooden cotton-tipped applicator)
Number of subjects: 95
Study 25845406 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagisan(®) Moisturising Cream (CREAM)
Number of subjects: 117
Study 25845406 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal vaginal gel (GEL)
Number of subjects: 117
Study 23273638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tualang honey (3 mls intraoperatively, followed by 4 mls orally three times daily for seven days) + Sultamicillin (25mg/kg IV three times daily for two days, then orally twice daily for five days)
Number of subjects: 63
Study 23273638 — intervention group
Group type: COMPARATOR
Intervention: Sultamicillin (25mg/kg IV for two days, then orally twice daily for five days)
Number of subjects: 63
Study 20084368 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg MDMA
Number of subjects: 16
Study 20084368 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg MDMA
Number of subjects: 16
Study 20084368 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 16
Study 20084368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18056887 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (multifaceted including an interactive meeting, a leaflet, a website, and a consultation with the diabetes care provider)
Number of subjects: 1124
Study 18056887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 1124
Study 16171020 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of 25% metronidazole-containing mucoadhesive lipogel
Number of subjects: 25
Study 16171020 — intervention group
Group type: COMPARATOR
Intervention: Control pockets (not treated with metronidazole)
Number of subjects: 25
Study 12849803 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo selection based on sequential evaluation of both pronuclear morphology and embryo morphology on day 3
Number of subjects: 441
Study 12849803 — intervention group
Group type: COMPARATOR
Intervention: Embryo selection based on only pronuclear morphology
Number of subjects: 441
Study 12849803 — intervention group
Group type: COMPARATOR
Intervention: Embryo selection based on only day‐3 embryo morphology
Number of subjects: 441
Study 10383498 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 500 mg, and amoxycillin 1000 mg (OAC)
Number of subjects: 160
Study 10383498 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, clarithromycin 250 mg, and metronidazole 400 mg (OMC)
Number of subjects: 160
Study 10383498 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily (O)
Number of subjects: 160
Study 8754956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 14
Study 8754956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1817620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D system (Bain) with 4 litre of oxygen per minute for 3 min
Number of subjects: 0
Study 1817620 — intervention group
Group type: COMPARATOR
Intervention: Triservice Anaesthetic Apparatus (TSA)
Number of subjects: 0
Study 7048776 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% 5-fluorouracil (5-FU) salicylic acid containing varnish
Number of subjects: 59
Study 7048776 — intervention group
Group type: COMPARATOR
Intervention: Varnish without 5-FU (placebo)
Number of subjects: 59
Study 28002986 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (1000 mg per day)
Number of subjects: 0
Study 28002986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27157472 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate (LC) diet
Number of subjects: 118
Study 27157472 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 118
Study 24817294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based calisthenic exercises
Number of subjects: 40
Study 24817294 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based calisthenic exercises
Number of subjects: 40
Study 24817294 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 40
Study 22308301 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 2774
Study 22308301 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 2774
Study 20942287 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints compound general anesthesia (group B)
Number of subjects: 90